Boudewijn van Vliet
Director/Board Member at PRYME N.V.
Boudewijn van Vliet active positions
Companies | Position | Start | End |
---|---|---|---|
PRYME N.V. | Director/Board Member | 10/02/2021 | - |
Director of Finance/CFO | - | - | |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Director/Board Member | 08/08/2023 | - |
Chairman | - | 08/08/2023 |
Career history of Boudewijn van Vliet
Statistics
International
Netherlands | 2 |
Switzerland | 2 |
Operational
Director/Board Member | 2 |
Director of Finance/CFO | 1 |
Chairman | 1 |
Sectoral
Industrial Services | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
PRYME N.V. | Industrial Services |
Private companies | 1 |
---|---|
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Health Technology |
- Stock Market
- Insiders
- Boudewijn van Vliet
- Experience